Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Quiz|Articles|March 22, 2026
Dermatology Times Spot Test: March 22, 2026
Author(s)Marie Bosslett, Assistant Editor
Listen
0:00 / 0:00
Key Takeaways
- A recurring “Spot Test” format is positioned as a weekly mechanism to reinforce dermatology fundamentals while sampling timely clinical and scientific developments.
- AAD Annual Meeting attendance and anticipation in Denver provides the framing for the week’s question set.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Advertisement
Welcome to Dermatology Times' Spot Test.
Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology. This week, we’re getting ready to head to Denver for the biggest dermatology conference of the year, the
Do you have a set of quiz questions to share? Contact editor Marie Bosslett at
According to late-breaking study data on baricitinib, what was the response time in adolescents, as shared by Anabela Cardoso, MD?
With the announcement of the benzoyl peroxide recall, what was Christopher Bunick, MD, PhD’s biggest tip for counseling patients?
In the late-breaking study data on delgocitinib for CHE, approximately what percentage of patients achieved at least one “deep response” criterion by week 16?
Advertisement
Related to this article
Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results, along with 3-year nemolizumab findings, upadacitinib switch data, and expert guidance on choosing a biologic in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
The Value of Precision Medicine in Atopic Dermatitis and Skin Cancers
2
JAK Inhibitor Safety in Atopic Dermatitis: Long-Term Epidemiology Data
3
No Observed Skin Lesion Flares After Switching to Upadacitinib in Atopic Dermatitis
4
Day 2 Recap: Fall Clinical 2026
5